Fitch Affirms BBB+ Ratings for Agilent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Ratings late on Tuesday affirmed several ratings of BBB+ for Agilent Technologies.

The BBB+ ratings, which translate to good credit quality, were affirmed for Agilent's Issuer Default Rating, senior unsecured revolving credit facility, and senior unsecured notes. Fitch's actions affect about $2.6 billion of debt, including an undrawn $400 million revolving credit facility that expires in 2016, Fitch said.

It rated Agilent's outlook Stable.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.